February 1, 2023
Daiichi Sankyo said on January 31 that its April-December sales grew 16.9% year on year, bolstered by the growth of its mainstay products such as the anticoagulant Lixiana (edoxaban) and the cancer med Enhertu (trastuzumab deruxtecan). The depreciating yen also...read more